Back to top
more

BioLineRx (BLRX)

(Real Time Quote from BATS)

$0.62 USD

0.62
60,688

-0.02 (-3.41%)

Updated May 17, 2024 10:36 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

BioLineRx Ltd. [BLRX]

Reports for Purchase

Showing records 21 - 40 ( 202 total )

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 21

12/16/2020

Company Report

Pages: 8

COMBAT Gives a Big Bloody Nose to Pancreatic Cancer; Target Increased to $22

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 22

08/06/2020

Company Report

Pages: 6

2Q20 Results; Motixafortide Could Be the Champion of 2H20

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 23

07/20/2020

Company Report

Pages: 7

COMBAT Approaching DEFCON 1 Against Pancreatic Cancer; Major Catalyst Imminent

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 24

03/12/2020

Company Report

Pages: 6

2019 Results; Mid-2020 Pancreatic Survival Data Critical to Thesis

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 25

01/22/2020

Daily Note

Pages: 4

COMBAT Fully Enrolls; Key Survival Data Mid-2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 26

01/17/2020

Daily Note

Pages: 3

Dropping Coverage Update

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 27

12/13/2019

Company Report

Pages: 10

Patience Appears to Be Paying off for COMBAT; Looking Forward to Next Steps

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 28

12/06/2019

Company Report

Pages: 10

Nice COMBAT First Look at Analyst Day Preps for ESMO Oral Next Week

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 29

11/12/2019

Company Report

Pages: 6

3Q19 Results; All Eyes on December 13 COMBAT Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 30

08/07/2019

Company Report

Pages: 6

2Q19 Results; BL-8040 Marching Towards Key Data in 2H19; Adjusting Post-Split Target to $18

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 31

05/14/2019

Company Report

Pages: 7

1Q19 Results; GENESIS Pushes Forward; Interim COMBAT Data Later This Year

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 32

03/28/2019

Company Report

Pages: 7

2018 Results; BL-8040 Profile Continues to Build Nicely; Target Adjusted to $3

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 33

12/11/2018

Company Report

Pages: 13

Investor Day Highlights BL-8040 Promise; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 50.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 34

11/09/2018

Company Report

Pages: 7

3Q18 Results; Continuing to Push BL-8040 Down the Field

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 35

10/22/2018

Company Report

Pages: 7

Pushing the Boulder Further up the Pancreatic Mountain

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 36

10/03/2018

Company Report

Pages: 6

Locking In More ''8040 Economics and Previewing COMBAT

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 37

08/14/2018

Company Report

Pages: 6

2Q18 Results; Getting Close to Significant Inflection Points; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 38

08/07/2018

Company Report

Pages: 6

Early Look at Phase 3 Lead-In Points to Getting Cells to Patients Faster

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 39

08/01/2018

Company Report

Pages: 6

AGI-134 Hits the Clinic as Expected; Dual-Pronged Mechanism Should Yield Intriguing Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 40

07/30/2018

Daily Note

Pages: 3

Study Expanding to Explore Third ''Punch''; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party